Small Gene Networks Delineate Immune Cell States and Characterize Immunotherapy Response in Melanoma.


Journal

Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637

Informations de publication

Date de publication:
03 08 2023
Historique:
received: 14 07 2022
revised: 14 12 2022
accepted: 23 05 2023
medline: 4 8 2023
pubmed: 25 5 2023
entrez: 25 5 2023
Statut: ppublish

Résumé

Single-cell technologies have elucidated mechanisms responsible for immune checkpoint inhibitor (ICI) response, but are not amenable to a clinical diagnostic setting. In contrast, bulk RNA sequencing (RNA-seq) is now routine for research and clinical applications. Our workflow uses transcription factor (TF)-directed coexpression networks (regulons) inferred from single-cell RNA-seq data to deconvolute immune functional states from bulk RNA-seq data. Regulons preserve the phenotypic variation in CD45+ immune cells from metastatic melanoma samples (n = 19, discovery dataset) treated with ICIs, despite reducing dimensionality by >100-fold. Four cell states, termed exhausted T cells, monocyte lineage cells, memory T cells, and B cells were associated with therapy response, and were characterized by differentially active and cell state-specific regulons. Clustering of bulk RNA-seq melanoma samples from four independent studies (n = 209, validation dataset) according to regulon-inferred scores identified four groups with significantly different response outcomes (P < 0.001). An intercellular link was established between exhausted T cells and monocyte lineage cells, whereby their cell numbers were correlated, and exhausted T cells predicted prognosis as a function of monocyte lineage cell number. The ligand-receptor expression analysis suggested that monocyte lineage cells drive exhausted T cells into terminal exhaustion through programs that regulate antigen presentation, chronic inflammation, and negative costimulation. Together, our results demonstrate how regulon-based characterization of cell states provide robust and functionally informative markers that can deconvolve bulk RNA-seq data to identify ICI responders.

Identifiants

pubmed: 37229623
pii: 726944
doi: 10.1158/2326-6066.CIR-22-0563
pmc: PMC10398358
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1125-1136

Informations de copyright

©2023 The Authors; Published by the American Association for Cancer Research.

Références

Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
Nat Methods. 2020 Feb;17(2):159-162
pubmed: 31819264
Genome Biol. 2014;15(12):550
pubmed: 25516281
Annu Rev Pathol. 2021 Jan 24;16:93-122
pubmed: 33497262
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Adv Immunol. 2011;111:179-206
pubmed: 21970955
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
EMBO J. 2000 May 2;19(9):1987-97
pubmed: 10790365
Nat Biotechnol. 2019 Jul;37(7):773-782
pubmed: 31061481
BMC Genomics. 2018 Jun 19;19(1):477
pubmed: 29914354
Bioinformatics. 2014 Jan 15;30(2):189-96
pubmed: 24292362
Nat Methods. 2013 Dec;10(12):1169-76
pubmed: 24296474
Nat Rev Immunol. 2020 May;20(5):294-307
pubmed: 31988391
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
Nat Commun. 2019 Sep 13;10(1):4186
pubmed: 31519915
Cells. 2020 Jun 24;9(6):
pubmed: 32599709
Cell. 2021 Apr 29;184(9):2487-2502.e13
pubmed: 33857424
Genes Dev. 2011 Sep 15;25(18):1915-27
pubmed: 21890647
Science. 2019 Dec 20;366(6472):
pubmed: 31857451
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
Nat Med. 2019 Aug;25(8):1251-1259
pubmed: 31359002
Cancer Cell. 2021 Jun 14;39(6):845-865.e7
pubmed: 34019806
R J. 2016 Aug;8(1):289-317
pubmed: 27818791
Cancer Cell. 2019 Feb 11;35(2):238-255.e6
pubmed: 30753825
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Immunity. 2019 Jan 15;50(1):195-211.e10
pubmed: 30635237
Immunity. 2018 Apr 17;48(4):659-674.e6
pubmed: 29669249
Nat Immunol. 2020 Dec;21(12):1552-1562
pubmed: 33046887
PLoS One. 2013 Oct 16;8(10):e76115
pubmed: 24146823
Nat Methods. 2017 Nov;14(11):1083-1086
pubmed: 28991892
Science. 2008 Oct 10;322(5899):271-5
pubmed: 18845758
Proc Natl Acad Sci U S A. 2021 Jun 1;118(22):
pubmed: 34001664
Nat Rev Immunol. 2021 Mar;21(3):162-176
pubmed: 32918063
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
JCO Oncol Pract. 2022 May;18(5):335-351
pubmed: 35133862
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
JAMA Netw Open. 2019 May 3;2(5):e192535
pubmed: 31050774
Exp Biol Med (Maywood). 2011 May 1;236(5):567-79
pubmed: 21486861
Commun Biol. 2022 May 30;5(1):510
pubmed: 35637301
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Front Immunol. 2018 Jul 30;9:1770
pubmed: 30131803
Nat Commun. 2020 Mar 5;11(1):1201
pubmed: 32139671
Cell Immunol. 2020 Jul;353:104118
pubmed: 32413598
Clin Cancer Res. 2022 May 13;28(10):2094-2109
pubmed: 35262677
Cell Rep. 2018 Nov 6;25(6):1436-1445.e3
pubmed: 30404000
Immunity. 2009 Dec 18;31(6):932-40
pubmed: 20064450
Nat Biomed Eng. 2018 Aug;2(8):578-588
pubmed: 31015631
Nat Rev Immunol. 2016 Oct;16(10):599-611
pubmed: 27526640
BMC Bioinformatics. 2020 Mar 18;21(1):110
pubmed: 32183729

Auteurs

Donagh Egan (D)

Precision Oncology Ireland, Systems Biology Ireland, School of Medicine, University College Dublin, Belfield, Republic of Ireland.

Martina Kreileder (M)

Precision Oncology Ireland, Systems Biology Ireland, School of Medicine, University College Dublin, Belfield, Republic of Ireland.

Myriam Nabhan (M)

Precision Oncology Ireland, Systems Biology Ireland, School of Medicine, University College Dublin, Belfield, Republic of Ireland.

Luis F Iglesias-Martinez (LF)

Precision Oncology Ireland, Systems Biology Ireland, School of Medicine, University College Dublin, Belfield, Republic of Ireland.

Simon J Dovedi (SJ)

AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom.

Viia Valge-Archer (V)

AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom.

Amit Grover (A)

AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom.

Robert W Wilkinson (RW)

AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom.

Timothy Slidel (T)

AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom.

Claus Bendtsen (C)

AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom.

Ian P Barrett (IP)

AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom.

Donal J Brennan (DJ)

Precision Oncology Ireland, Systems Biology Ireland, School of Medicine, University College Dublin, Belfield, Republic of Ireland.
Catherine McAuley Research Centre Mater Misericoridae University Hospital, Dublin, Republic of Ireland.

Walter Kolch (W)

Precision Oncology Ireland, Systems Biology Ireland, School of Medicine, University College Dublin, Belfield, Republic of Ireland.
Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Belfield, Ireland.

Vadim Zhernovkov (V)

Precision Oncology Ireland, Systems Biology Ireland, School of Medicine, University College Dublin, Belfield, Republic of Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH